Specialty Pharmacy

Work is still needed to achieve the significant promise of mobile health applications.

Specially synthesized plant peptide cyclotide found to suppress onset of multiple sclerosis.

Looming clinical trials offer hope for patients with Parkinson’s disease.

Study finds need for improved understanding of the association between rising systemic therapy use and the uptake of palliative care.

Inhibiting newly classified enzymes may lead to treatments for type 2 diabetes, inflammation, and autoimmune disease.

Cancer’s long-term side effects on fertility should be discussed with parents of young cancer patients.

Top news of the day from across the health care landscape.

Statins may reduce morbidity and/or mortality in COPD patients.

Inflectra biosimilar treats conditions such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Program leads to estimated Medicare savings of $2650 for each enrollee over a 15-month period.

Top news of the day from across the health care landscape.

While PSA levels decreased in patients, overall survival did not improve in patients with non-metastatic prostate cancer.

New system could lead to advances in cancer investigation and drug discovery.

Study finds 15.5% of all psoriasis patients had undiagnosed psoriatic arthritis.

Lamivudine is designed to treat HIV-1 infection in combination with other antiretroviral agents.

Lamivudine is a nucleoside analogue reverse transcriptase inhibitor designed to treat HIV-1 infection in combination with other antiretroviral agents.

Venetoclax (Venclexta)is the first treatment approved by the FDA that inhibits the B-cell lymphoma 2 (BCL-2) protein.

A flood of new therapies approved last year offer new hope for patients with multiple myeloma.

New technique allows physicians to see if a tumor is susceptible or resistant to treatment much earlier than conventional methods.

Findings on x-linked reticulate pigmentary disorder (XLPDR) could lead to new targeted therapies.

Marc O'Connor, chief operating officer of Curant Health, discusses efficiency in specialty pharmacy relationships.

Atezolizumab treats locally advanced or metastatic NSCLC expressing the PD-L1 protein.

Top news of the day across the health care landscape.

There are currently no treatments deemed effective in slowing down the progression of FTD.

A large proportion of patients with multiple sclerosis experience taste deficits.

A better understanding of the dynamics of the immune system's response to HIV may lead to more effective IFNa-based therapies.

Top articles of the week from The American Journal of Pharmacy Benefits.

Low oxygen conditions encourage some cancer stem cells to multiply.